Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05013099 · ClinicalTrials.gov registry record · Phase 2
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
A Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by ImaginAb.
- Active
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 16
- Study locations
NCT05013099: Active Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by ImaginAb.
NCT05013099 is a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma that is active but no longer recruiting, run by ImaginAb. The registered enrollment target is 70 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05013099, a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, is active but no longer recruiting, sponsored by ImaginAb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to evaluate whether zirconium Zr 89 crefmirlimab berdoxam (other names 89Zr-crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C) PET/CT can predict the response of advanced or metastatic melanoma, Merkel cell carcinoma, renal cell carcinoma, or non-small cell lung cancer tumors to immuno-oncology therapy.
Conditions Studied
Interventions
- BIOLOGICAL zirconium Zr 89 crefmirlimab berdoxam
Study Locations (16)
Other
- University Hospitals Leuven - Leuven
- Leiden University Medical Center - Leiden
- Lausanne University Hospital - Lausanne
- Northern Centre for Cancer Care and Newcastle University - Newcastle upon Tyne
California
- City of Hope - Duarte
- Providence Saint John's Cancer Institute - Santa Monica
Victoria
- Olivia Newton-John Cancer Research Insititute - Heidelberg
- Peter MacCallum Cancer Centre - Melbourne
Arkansas
- CARTI Cancer Center - Little Rock
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- UT Southwestern Medical Center - Dallas
Washington
- University of Washington - Seattle
New South Wales
- Macquarie University Hospital - Macquarie Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-12-09 |
| Est. Completion | 2025-07 |
| Phase | Phase 2 |
What the registry record for NCT05013099 still lists
NCT05013099 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower).
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which zirconium Zr 89 crefmirlimab berdoxam is the first listed.
NCT05013099 lists 16 locations in 11 states (Other, California, Victoria).
Frequently Asked Questions
What is clinical trial NCT05013099 about?
NCT05013099 is a clinical study titled "Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies". The purpose of this study is to evaluate whether zirconium Zr 89 crefmirlimab berdoxam (other names 89Zr-crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C) PET/CT can predict the response of advanced or metastatic melanoma, Merkel cell carcinoma, renal cell carcinoma, or non-small cell l...
What is the current status of trial NCT05013099?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2021-12-09. Estimated completion is 2025-07.
What conditions does trial NCT05013099 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Merkel Cell Carcinoma, Unspecified.
What interventions are being tested in trial NCT05013099?
The interventions under investigation include: zirconium Zr 89 crefmirlimab berdoxam (BIOLOGICAL).
Who is sponsoring clinical trial NCT05013099?
This trial is sponsored by ImaginAb, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05013099 being conducted?
This trial has 16 study locations across Arkansas, California, New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05013099's enrollment target sits among peer trials
70 289th of 454 higher than 161 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI